Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1995-02-01
2001-09-25
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S001490, C424S009100, C424S130100, C424S133100, C424S141100, C424S174100, C424S178100, C424S138100, C435S007100, C435S007200, C435S007210, C435S007230, C435S326000, C435S332000, C435S344000, C435S344100, C530S387100, C530S387700, C530S388100, C530S388200, C530S388800, C530S388850, C530S413000, C536S023100, C536S023500, C536S023530
Reexamination Certificate
active
06294172
ABSTRACT:
The invention relates to monoclonal antibodies which bind to defined membrane-associated antigens. These antibodies can be used as diagnostic aids, active compounds, or as carriers of active compounds.
In addition, it is known, for example from “Mechanisms of Tumor Immunity,” Gree et al., eds., John Wiley and Sons, N.Y., 1977, page 196, that attempts have already been made to treat tumorous diseases by inoculation with tumor cells which have been modified by freezing and thawing, freeze-drying, pressure or homogenization. Subcellular fractions or cell extracts have also been used for this purpose. However, as of yet no vaccine against a tumorous disease has been disclosed. Thus, the invention further relates to a process for the preparation of therapeutic agents from tumor cells for the therapy of tumorous diseases, to a therapeutic agent of this type, and to its use for the therapy of tumors.
The invention also relates to the use of monoclonal antibodies (MAB or Ab) or other ligands which have the property of binding to pancreatic carcinoma cells and of blocking at least one of the following cellular functions: pinocytosis of colloidal gold, production of superoxide anion or release of enzymes, especially of neutral proteases, very especially collagenase or elastase, of growth factor, colony-stimulating factor, erythropoietin, fibroblast growth factor, tumor angiogenesis factor or transforming growth factor, for tumor therapy. The molecules designated as ligands are not monoclonal antibodies but they also bind to pancreatic carcinoma cells and inhibit their cellular functions, for example, certain hormones.
Processes suitable for the preparation of monoclonal antibodies of these types are described in European Patent A-0 160 897, in German Offenlegungsschrift 33 29 184 and in German Patent Application 35 31 301 (filed on Sep. 2, 1985). The technique of immunization with defined isolated antigens and the production of antibodies to antigens of these types are known. Immunization with unpurified antigenic material, and the selection of those antibodies which recognize a particular component in a mixture of antigens of this type are also known.
In the attempt to induce antibodies of these types, it has been possible to select monoclonal antibodies which, under non-reducing conditions, react with the following protein antigens or particular epitopes on these protein antigens: antigen 1: MW 33 KD±3, antigen 2: MW 134 KD±3, antigen 3: MW 80 KD±3, antigen 4: MW 55 KD±3, antigen 5: MW 60 KD±3, antigen 6: MW 54 KD±3, antigen 7: MW 260 KD±3, antigen 8: MW not determinable, antigen 9: MW not determinable, antigen 10: MW 143 KD±3, 119 KD±3, antigen 11: MW 178 KD±3, antigen 12: MW not determinable, antigen 13: MW 34 KD±3, antigen 14: MW 195 KD±3, antigen 15: MW 44 KD±7, antigen 16: MW 43 KD±3, and antigen 17: MW 130 KD±3. It has also been possible to select monoclonal antibodies which, under non-reducing or reducing conditions, react with the following protein antigens or particular epitopes on these protein antigens: antigen 18: MW 72±3 KD, under non-reducing or reducing conditions, antigen 19: MW>200 KD under non-reducing conditions, antigen 20: three glycoproteins of MW 180±10 KD, MW 95±10 KD and 55±10 KD under non-reducing or reducing conditions, and antigen 21: MW>200 KD under non-reducing conditions. These antigens and antibodies are defined in greater detail in the descriptions and examples which follow.
The epitopes on antigens 1-21 which are recognized by Ab 1-21 differ in their sensitivity to treatment with dithiothreitol (50 mmol/l, 2 h, 37° C.): the epitopes of Ag 1, 2 and 15 are modified by the above treatment, while those of Ag 4, 10 and 14 remain unmodified.
The antigens 4, 8, 9 and 10 are mycoplasma antigens which are associated with the cell lines described in the table. The remaining antigens are human cell lines cultured in vitro, cell extracts or extracts of human tissues. Permanent human cell lines, in particular the CaLu-1, Chago, Oat 75, PaTu II and Bewo cell lines, are preferred. It is also possible to use Ag 1-Ag 21 to induce Ab 1-Ab 21.
REFERENCES:
patent: 3862925 (1975-01-01), Sarantakis et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4349528 (1982-09-01), Koprowski et al.
patent: 4444744 (1984-04-01), Goldenberg
patent: 4446240 (1984-05-01), Nerenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4485093 (1984-11-01), Runge
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4569788 (1986-02-01), Mulshine et al.
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4582797 (1986-04-01), Trowbridge
patent: 4585742 (1986-04-01), Bernal
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4645828 (1987-02-01), Twardzik et al.
patent: 4677058 (1987-06-01), Tryggvason et al.
patent: 4683200 (1987-07-01), Hirohashi et al.
patent: 3 329 184 (1985-02-01), None
patent: 3329184 (1985-02-01), None
patent: A 0098162 (1984-01-01), None
patent: 0118365 (1984-09-01), None
patent: A 0118365 (1984-09-01), None
patent: A0141079 (1985-05-01), None
patent: 0151030A2 (1985-08-01), None
patent: A0153114 (1985-08-01), None
patent: A0160446 (1985-11-01), None
patent: 0189849A2 (1986-08-01), None
patent: 1193378 (1970-05-01), None
patent: WO-A8101469 (1981-05-01), None
Bosslet et al. Cancer Detection and Prevention 6:181-184 (1983).*
Waldmann Science 252:1657-1662 (1991).*
Harris et al. TIBTECH 11:42-46 (1993).*
Osband et al. Immunotherapy 11(6):193-195 (1990).*
Dillman Ann. Internal Med. 111:592-603 (1989).*
Hird et al. Genes and Cancer , published 1990 by Wiley & Sons Ltd, chapter 17, ed. Carnet et al. pp 183-189.*
Electorphoresis, Theory, Techniques, and Biochemical and Clinical Applications2 ed., Oxford Science Publications p. 98 (1986).*
Dillman J Clin Oncology 12: 1497-1575, 1994.*
Bosslet et al. Cancer Immunol. Immunother 23: 185-191, 1986.*
Lembersky Semiwars in Oncology 18(Suppl.) :39-46, 1991.*
ATCC Cell Lines and Hybridoms, 8th Edition 1994 American Type Cultures Coucerow, Rockville MD pp. 59, 266, 311.*
Hand et al,Cancer Research, 45, 833-840, 1985.*
Talalay, P., et al., “Chromogenic Substrates, II. Phenolphthalein Glucuronic Acid as Substrate for the Assay of Glucuronidase Activity,” J. Biol. Chem., 166:757-772 (1946).
Conchie, J., et al., “Mammalian Glycosidases, Distribution in the Body,” Biochem., 71:318-325 (1959).
Davies, P., et al., “The Quantitative Estimation of Pinocytosis Using Radioactive Coloidal Gold,” Biochemical and Biophysical Research Communications, 52(2) :627-634 (1973).
Lieber, M., et al., Establishment of a Continuous Tumor-Cell Line (PANC-1) From a Human Carcinoma of the Exocrine Pancreas, Int. Cancer, 15:741-747 (1975).
Bosslet, K., et al., “Monoclonal Murine Antibodies with Specificity for Tissue Culture Lines of Human Squamous-Cell Carcinoma of the Lung,” Cancer Detection and Prevention, 6:181-184 (1983).
Herlyn, D., et al., “Inhibition of Human Tumor Growth by IqG2a Monoclonal Antibodies Correlates with Antibody Density on Tumor Cells,” J. Immunology, 134(2) :1300-1304 (Feb. 1985).
Brown, J., et al., “A Microassay for Antibody Binding to Tumor Cell Surface Antigens Using125-Labelled Protein A fromStaphylococcus Aureus, ” J. Immunological Methods, 15:57-66 (1977).
Heyderman, E., “Immunoperoxidase Technique in Histopathology: Applications, Methods and Controls,” J. Clinical Pathology, 32:971-978 (1979).
Bosslet, K., et al., “Molecular Characteristics of Two Lung Carcinoma Cell-Line Associated Membrane Antigens,” Behring Inst. Mitt, 74:27-34 (1984).
Meeting Highlights, “Breast Cancer, Epithelial Cells, and Extracellular Matrix,” JNCI, 73(4) :999-1001 (Oct. 1984).
Wilson, B., et al., “Human Melanoma-associated Antigens Identified with Monoclonal Antibodies,” La Ricerca Clin. Lab., 12:517-538 (1982).
Loop, S., et al., “Human Tumor-associated Antigens, p155 and p210, Detected by Monoclonal Antibodies,” Biological Abstracts, vol. 73, Heft 1, p. 431, col. 2, Abstract No. 4132 (1982) ; abstract, Int. J. Can
Bosslet Klaus
Kanzy Ernst-Jurgen
Katoh Takako
Kurrle Roland
Luben Gerhard
Dade Behring Marburg GmbH
Finnegan, Henderson Farabow, Garrett and Dunner L.L.P.
Gambel Phillip
LandOfFree
Monoclonal antibodies with specificity for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies with specificity for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies with specificity for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2480172